Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients

Marian K. Bakker,Jean-Pierre Droz,A.-R. Hanauske,Jaap Verweij,A. van Oosterom,H. Groen,Ma Pacciarini,L Domenigoni,F van Weissenbruch,E Pianezzola,Ege de Vries

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients

1998

Marian K. Bakker
Jean-Pierre Droz
A.-R. Hanauske
Jaap Verweij
A. van Oosterom
H. Groen
Ma Pacciarini
L Domenigoni
F van Weissenbruch
E Pianezzola
Ege de Vries

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients

Keywords:

Medicine
Respiratory disease
Immunology
Pathology
Doxorubicin
Cancer
Lung cancer
Kidney disease
Epirubicin
Pharmacokinetics
Chemotherapy
Volume of distribution
Toxicity
Bolus (digestion)
Neutropenia
Vomiting

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations